BioCentury
ARTICLE | Company News

Codiak, Jazz to develop exosomes against tricky oncogenes

January 4, 2019 6:54 PM UTC

Codiak BioSciences Inc. (Cambridge, Mass.) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) partnered to develop exosome therapies for hard-to-treat cancers.

Jazz gains exclusive, worldwide rights to develop, manufacture and commercialize exosome candidates against five oncogene targets for hematological malignancies and solid tumors to be developed using Codiak's engEx precision engineering platform. The deal includes therapies against neuroblastoma Ras viral oncogene (NRAS) and signal transducer and activator of transcription 3 (STAT3), both of which are historically undruggable intracellular targets. Two targets remain undisclosed, and the partners have not decided on the fifth, according to Codiak President and CEO Douglas Williams...